NCI Stock Recent News

NCI LATEST HEADLINES

NCI Stock News Image - prnewswire.com

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the potential to substantially increase the market opportunity.

prnewswire.com 2025 Apr 24
NCI Stock News Image - globenewswire.com

HONG KONG, April 01, 2025 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) is excited to announce the soft opening of its very first Les100Ciels store in the Middle East and North Africa (MENA) region! Located at The Galleria Al Maryah Island in Abu Dhabi, which took place on March 27, 2025.

globenewswire.com 2025 Apr 01
NCI Stock News Image - globenewswire.com

HONG KONG, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”) announced that it received a letter from Nasdaq on January 7, 2025, indicating that the Company is granted an additional 180 calendar days, until July 7, 2025, to regain compliance with the minimum bid price requirement of $1 per share, as stipulated by Nasdaq Listing Rule 5550(a)(2).

globenewswire.com 2025 Jan 08
NCI Stock News Image - globenewswire.com

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 - 25, 2024. Details on the posters are below.

globenewswire.com 2024 Oct 10
NCI Stock News Image - globenewswire.com

CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer

globenewswire.com 2024 Oct 10
NCI Stock News Image - globenewswire.com

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities

globenewswire.com 2024 Oct 09
NCI Stock News Image - globenewswire.com

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –

globenewswire.com 2024 Oct 09
NCI Stock News Image - globenewswire.com

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST)

globenewswire.com 2024 Oct 09
NCI Stock News Image - globenewswire.com

Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema's KAT6 inhibitor, in combination with palazestrant and other targeted agents Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema's KAT6 inhibitor, in combination with palazestrant and other targeted agents

globenewswire.com 2024 Oct 09
NCI Stock News Image - globenewswire.com

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations

globenewswire.com 2024 Oct 07
10 of 18